Omalizumab Subcutaneous and Malignancies
Result of checking the interaction of drug Omalizumab Subcutaneous and disease Malignancies for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:In clinical trials malignancies have been observed in patients receiving omalizumab. Periodic examination is recommended for all patients, particularly those with risk factors for cancer. Caution should be exercised when considering omalizumab for the treatment of patients with a history of malignancies, those who have a known malignancy, or when continuing treatment in patients who develop malignancy while receiving this agent.
Generic Name: omalizumab
Brand Name: Xolair, Xolair Prefilled Syringe
Synonyms: Omalizumab
Omalizumab Subcutaneous - nowotwory złośliwe 
Omalizumab Subcutaneous - malignidades 
Omalizumab Subcutaneous - keganasan 
Omalizumab Subcutaneous - keganasan 
Omalizumab Subcutaneous - tumori maligni 
Omalizumab Subcutaneous - tumeurs malignes 
Omalizumab Subcutaneous - bösartige Erkrankungen 
Omalizumab Subcutaneous - malignidades 
Omalizumab Subcutaneous - злокачественные новообразования 
Omalizumab Subcutaneous - maligniteler 
Omalizumab Subcutaneous - الأورام الخبيثة 
Omalizumab Subcutaneous - 恶性肿瘤